Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 3241 - 3248 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC7812 | OPC 21268 |
|
Nonpeptide vasopressin V1 receptor antagonist. Displays greater affinity for rat V1 than human V1 (Ki values are 25 and 8800 nM respectively). Exhibits 1000-fold selectivity for V1 receptors over V2 receptors. Orally active.
|
|
| BCC7813 | WAY 267464 dihydrochloride |
|
Potent, selective non-peptide oxytocin receptor (OTR) agonist (K<sub>i</sub> = 58.4 nM at human OTR). Exhibits anxiolytic-like effects. May have therapeutic potential for the treatment of psychosis and schizophrenia.
|
|
| BCC7814 | CDP 840 hydrochloride |
|
Potent and selective inhibitor of phosphodiesterase (PDE) 4 (IC50 = 12 nM for native PDE4). Competitively inhibits all PDE4 isoenzymes (IC50 values are 4, 9, 9 and 45 nM for PDE4A, PDE4B, PDE4C and PDE4D human recombinant isoforms expressed in yeast).
|
|
| BCC7815 | ANR 94 |
|
Adenosine A2A receptor (AA2AR) antagonist (Ki values are 643 and 46 nM for rat and human AA2ARs respectively). Most active AA2AR antagonist for human receptors. Displays activity in the treatment of Parkinson's disease in vivo; improves parkinsonian motor deficits and tremors. Exhibits neuroprotective and anti-inflammatory effects.
|
|
| BCC7816 | TCS 5861528 |
|
TRPA1 channel blocker that antagonizes AITC- and 4-HNE-evoked calcium influx (IC<sub>50</sub> values are 14.3 and 18.7<span class='symbol'>μ</span>M respectively). Attenuates diabetic hypersensitivity in an <em>in vivo</em> rat model.
|
|
| BCC7817 | YM 58483 |
|
Blocker of store-operated Ca2+ entry (SOCE), which mediates the activation of non-excitable cells (e.g. lymphocytes). Inhibits calcium release-activated calcium (CRAC) channels; suppresses thapsigargin-induced sustained Ca2+ influx (IC50 = 100 nM). Displays immuno-modulatory and anti-inflammatory effects; suppresses cytokine production and proliferation of T cells in vitro.
|
|
| BCC7818 | GSK 789472 hydrochloride |
|
Selective dopamine D3 receptor antagonist and D2 partial agonist (pEC50 values are <5.5 and 8.3 respectively). Selective against the D4 receptor in both agonist and antagonist assays. Brain penetrant.
|
|
| BCC7819 | TCS 1205 |
|
GABA<sub>A</sub> <span class='symbol'>α</span>2 agonist and GABA<sub>A</sub> <span class='symbol'>α</span>1 partial agonist <em>in vitro</em> (K<sub>i</sub> values are 14 and 121 nM respectively). Exhibits non-sedative anxiolytic activity <em>in vivo</em>.
|
|